Bayforest Capital LTD Alkermes Plc. Transaction History

Bayforest Capital LTD

  • $210 Billion
  • Q3 2025

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Jul 28, 2025
BUY
$26.59 - $32.65 $52,435 - $64,385
1,972 Added 21.27%
11,242 $322 Million
Q1 2025

May 08, 2025
BUY
$28.08 - $36.0 $133,436 - $171,072
4,752 Added 105.18%
9,270 $164 Million
Q4 2024

Feb 14, 2025
BUY
$25.7 - $31.46 $116,112 - $142,136
4,518 New
4,518 $130 Million

Others Institutions Holding ALKS

# of Institutions
400
Shares Held
176M
Call Options Held
901K
Put Options Held
400K
View Full List

About Alkermes plc.

ALKS Quotes by TradingView
  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.77B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Bayforest Capital LTD Portfolio

Follow Bayforest Capital LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bayforest Capital LTD, based on Form 13F filings with the SEC.

News

Stay updated on Bayforest Capital LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email